In August 2025, Serena Williams disclosed that she had used Zepbound (tirzepatide), prescribed through the telehealth company Ro, to address postpartum weight she said she had been unable to shift through training and diet alone.^[1] Speaking to Today, she reported a loss of roughly 31 pounds and framed the experience as a shift in how she understood her own physiology. 'I realized it wasn't about willpower,' she said. 'It was biological.'^[1]

The public record of the disclosure

Williams's disclosure did not happen in a vacuum. It was made in the context of a paid partnership with Ro, the telehealth platform through which she received the prescription.^[2] Coverage at the time also noted that her husband, Alexis Ohanian, is an investor in Ro and sits on the company's board.^[2] Those facts do not invalidate the personal experience she described. They belong in any honest account of the disclosure, and reputable coverage — including NBC News's reporting — has included them alongside her statements.

The regulatory category she was operating within

Zepbound is the brand name for tirzepatide as approved by the FDA for chronic weight management in adults meeting specified BMI criteria and, in a subsequent expanded indication, for moderate-to-severe obstructive sleep apnea in adults with obesity.^[3] It is a prescription medication dispensed by a licensed pharmacy under a prescriber's order. That places Williams's experience inside the approved-drug regulatory system — a meaningfully different category from 'research use only' tirzepatide sold through online chemical sellers, which the FDA has explicitly warned against.^[4]

For a reader trying to place the disclosure inside the broader Half-Life frame: this is a story about an approved prescription drug being used through a licensed telehealth channel. It is not a story about research peptides.

What she reframed, and why it registered

The willpower framing of obesity — the assumption that a person's body weight is primarily an index of their moral discipline — has dominated American popular discourse for decades and is not well supported by current endocrinology. Body weight is regulated by an interlocking system of appetite-signaling peptides (leptin, ghrelin, GLP-1, PYY, and others), central nervous system set points, and metabolic feedback loops. That system does not respond uniformly to conscious effort, especially after events — pregnancy, illness, aging — that alter the underlying signaling.

A widely known athlete saying out loud that her postpartum weight responded to a drug targeting appetite-regulating hormones — rather than to additional discipline — is a piece of that cultural record. It is not, by itself, a scientific claim. It is a data point about how the framing is shifting in public conversation, alongside similar disclosures from Oprah Winfrey and others.

What the underlying trial evidence measured

The trial evidence behind the drug Williams described captures more than kilograms lost. In SURMOUNT-1, the pivotal phase III trial of tirzepatide for chronic weight management, participants receiving active drug reported improvements over placebo on the SF-36 physical-functioning score and the IWQOL-Lite-CT — validated patient-reported outcome instruments that measure how obesity affects daily physical activity and quality of life.^[5] Those trial-level findings do not translate one person's experience into a claim about anyone else's, but they do describe, in structured terms, what the drug class has been shown to shift for patients in the approved indication.

How to read a disclosure with a commercial layer

Two things can be true at once: the medical experience Williams described can be genuine, and the paid partnership she disclosed can be a commercial relationship that shapes how the story is told and where it appears. The FTC's endorsement guidelines require disclosure of material connections between endorsers and brands; the disclosure Williams and Ro made appears designed to comply. Readers evaluating the story are best served by holding both the personal report and the commercial context in the same frame, rather than collapsing to one or the other.

What this profile is not

Half-Life publishes no product links on profile pieces, and does not use profiles to endorse or advise against any medication. Williams's experience is her own, reported through her own channels, describing an FDA-approved prescription drug prescribed and dispensed under the standard rules that govern that class. This profile is a record of that public conversation, not a recommendation.